High-Dose Resveratrol Supplementation in Obese Men

An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition

  1. Jens Otto L. Jørgensen1
  1. 1Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
  2. 2Institute of Chemical Engineering, Biotechnology and Environmental Technology, University of Southern Denmark, Odense, Denmark
  3. 3Magnetic Resonance Research Centre, Aarhus University Hospital, Aarhus, Denmark
  4. 4Department of Pharmacology, Aarhus University Hospital, Aarhus, Denmark
  1. Corresponding author: Morten M. Poulsen, mmp{at}ki.au.dk.

Abstract

Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.

Footnotes

  • Received July 31, 2012.
  • Accepted October 23, 2012.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

No Related Web Pages
| Table of Contents

This Article

  1. Diabetes vol. 62 no. 4 1186-1195
  1. Supplementary Data
  2. News Release
  3. All Versions of this Article:
    1. db12-0975v1
    2. 62/4/1186 most recent